ZEALAND PHARMA A/S — Credit Rating and Financial Key Figures
CVR number: 20045078
Sydmarken 11, 2860 Søborg
info@zealandpharma.com
tel: 88773600
http://www.zealandpharma.com
Income statement (mDKK)
2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Fiscal period length | 12 | 12 | 12 | 12 | 12 |
| Net sales | 192.00 | 108.55 | 103.99 | 342.79 | 62.69 |
| Other operating income | 15.98 | ||||
| Costs of manufacturing | - 818.24 | - 881.89 | - 941.14 | -10.04 | -7.87 |
| Gross profit | 192.00 | 97.58 | 103.99 | 323.61 | 54.82 |
| Costs of management | - 201.59 | - 235.61 | - 237.21 | - 185.30 | - 315.91 |
| Costs of marketing | -20.80 | -62.60 | -32.30 | -30.63 | -88.11 |
| Other operating expenses | 222.39 | 287.24 | 269.51 | - 705.04 | - 923.00 |
| EBIT | - 626.24 | - 784.32 | - 837.15 | - 572.24 | -1 272.21 |
| Other financial income | 2.02 | 41.21 | 133.27 | 54.12 | 240.26 |
| Other financial expenses | -49.31 | -15.78 | - 268.16 | - 190.74 | -51.50 |
| Pre-tax profit | - 673.53 | - 758.89 | - 972.04 | - 708.87 | -1 083.44 |
| Income taxes | 4.81 | 3.95 | 6.43 | 5.13 | 4.62 |
| Profit/loss from discontinued operations | - 178.02 | - 263.21 | - 236.53 | ||
| Net earnings | - 846.73 | -1 018.15 | -1 202.13 | - 703.74 | -1 078.83 |
Assets (mDKK)
2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Intangible rights | 53.79 | 12.26 | 12.62 | ||
| Intangible assets total | 53.79 | 12.26 | 12.62 | ||
| Other tangible assets | 86.45 | 50.53 | 47.05 | 46.48 | |
| Tangible assets total | 86.45 | 50.53 | 47.05 | 46.48 | |
| Other non-current investments | 161.90 | 152.80 | 124.18 | 898.40 | |
| Investments total | 161.90 | 152.80 | 124.18 | 898.40 | |
| Non-current other receivables | 29.09 | 18.11 | 15.79 | 19.41 | |
| Deferred tax assets | 14.79 | 2.02 | 0.93 | 0.98 | |
| Long term receivables total | 43.89 | 20.12 | 16.72 | 20.40 | |
| Inventories total | 118.44 | 1.29 | 7.93 | 10.70 | |
| Current trade debtors | 153.45 | 115.62 | 97.80 | 193.56 | |
| Current other receivables | - 960.22 | 299.04 | - 240.00 | 1 208.30 | 7 809.29 |
| Current deferred tax assets | 21.56 | 21.60 | 16.44 | 10.23 | |
| Fair value of financial assets | 23.63 | ||||
| Short term receivables total | - 960.22 | 474.06 | - 102.78 | 1 322.54 | 8 036.70 |
| Cash and bank deposits | 960.22 | 1 129.10 | 1 417.84 | 449.31 | 480.30 |
| Cash and cash equivalents | 960.22 | 1 129.10 | 1 417.84 | 449.31 | 480.30 |
| Balance sheet total (assets) | 2 067.63 | 1 539.81 | 1 979.99 | 9 505.60 |
Equity and liabilities (mDKK)
2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Share capital | 43.63 | 51.70 | 58.75 | 71.02 | |
| Share premium account | 4 921.23 | 6 406.23 | 14 680.77 | ||
| Other reserves | 1 229.31 | 884.17 | 14.62 | 22.70 | 22.39 |
| Retained earnings | 846.73 | 1 018.15 | -2 969.51 | -4 191.10 | -5 078.61 |
| Profit of the financial year | - 846.73 | -1 018.15 | -1 202.13 | - 703.74 | -1 078.83 |
| Shareholders equity total | 1 229.31 | 927.80 | 815.91 | 1 592.84 | 8 616.74 |
| Non-current loans from credit institutions | 647.91 | 401.35 | 285.33 | ||
| Non-current leasing loans | 124.63 | 108.00 | 102.58 | 90.39 | |
| Non-current other liabilities | 32.98 | 19.06 | 109.67 | ||
| Non-current liabilities total | 805.51 | 528.40 | 102.58 | 485.38 | |
| Current leasing loans | 14.90 | 14.73 | 16.66 | 16.04 | |
| Current trade creditors | 266.39 | 180.76 | 125.07 | 254.84 | |
| Other non-interest bearing current liabilities | -1 229.31 | 142.85 | 132.59 | ||
| Accruals and deferred income | 53.03 | ||||
| Current liabilities total | -1 229.31 | 334.32 | 195.49 | 284.58 | 403.47 |
| Balance sheet total (liabilities) | 2 067.63 | 1 539.81 | 1 979.99 | 9 505.60 |
Try the full version of our system for free
Create your own estimates for any company
Valuation analysis
See instructions
... and more!
No registration needed.